KONINKLIJKE PHILIPS NV ADR EACH REP 1 ORD EUR0.20

KONINKLIJKE PHILIPS NV ADR EACH REP 1 ORD EUR0.20

Koninklijke Philips N.V. (PHG) is a Dutch health‑technology company that designs and sells medical devices and related services across diagnostic imaging, patient monitoring, and respiratory care. After refocusing away from consumer appliances, Philips now emphasises hospital equipment, connected care and health informatics β€” areas driven by ageing populations and digital healthcare adoption. Investors should note a market capitalisation around $27.5 billion and a business mix of product sales, long‑term service contracts and software subscriptions, which can smooth revenues but requires sustained R&D and capital investment. Key considerations include regulatory scrutiny, product quality and lingering legal exposures from past device issues, alongside competition from larger medical‑device peers. Financial metrics to watch are order backlog, service revenue growth, margins and free cash flow. This is general information for educational purposes only; it is not investment advice and investors should assess suitability against their own objectives and risk tolerance.

Why It's Moving

KONINKLIJKE PHILIPS NV ADR EACH REP 1 ORD EUR0.20

PHG Analysts Lean Buy Amid Upward Earnings Revisions and Healthcare Innovation Buzz

Analysts are warming to Koninklijke Philips (PHG) with a consensus tilting toward buy ratings, fueled by recent upward tweaks to 2026 earnings forecasts. This optimism underscores the company's potential in healthcare tech amid a stabilizing sector outlook.
Sentiment:
πŸƒBullish
  • Two analysts lifted 2026 earnings estimates in the last 60 days, pushing the consensus to $1.88 per share and signaling confidence in Philips' growth trajectory.
  • Consensus ratings show 2 buys, minimal holds, and no sells, reflecting belief in PHG's innovative product pipeline driving future revenue.
  • PHG's average earnings surprise of +46.4% highlights its track record of outperforming expectations, bolstering long-term value appeal.

When is the next earnings date for KONINKLIJKE PHILIPS NV ADR EACH REP 1 ORD EUR0.20 (PHG)?

Koninklijke Philips N.V. (PHG) is scheduled to release its next earnings on May 6, 2026, before market open, covering the first quarter of 2026 results. This follows the company's most recent Q4 2025 report on February 10, 2026. Investors should monitor for any official confirmation from the company as the date approaches.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Philips stock, with a target price indicating potential for growth.

Above Average

Financial Health

Philips is performing well with solid revenue and cash flow, though margins could improve.

Below Average

Dividend

Philips' below average dividend yield of 0.99% may not be appealing for dividend-seeking investors. If you invested $1000 you would be paid $9.90 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Discover More Opportunities

ABT

Abbott

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

A

AGILENT TECHNOLOGIES INC

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

ALGN

ALIGN TECHNOLOGY INC

Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.

Baskets Featuring PHG

Healthcare Innovation: MedTech Giants Portfolio 2025

Healthcare Innovation: MedTech Giants Portfolio 2025

Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.

Published: September 22, 2025

Explore Basket

Why You’ll Want to Watch This Stock

πŸ“ˆ

Recurring revenue mix

Services and software subscriptions can stabilise revenue streams, though growth depends on hospital budgets and successful product roll‑outs.

🌍

Global healthcare trends

Ageing populations and digital health uptake support long‑term demand, while emerging‑market expansion offers opportunity amid local competition.

⚑

Regulatory and quality focus

Product safety and regulatory compliance are critical; past device issues highlight the potential for reputational and financial impact.

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions